Critical COVID-19 patients through first, second, and third wave: retrospective observational study comparing outcomes in intensive care unit.

Coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) intensive care unit (ICU) mechanical ventilation treatment

Journal

Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 02 06 2022
accepted: 02 12 2022
medline: 10 7 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: ppublish

Résumé

The time-course of the coronavirus disease 2019 (COVID-19) pandemic was characterized by subsequent waves identified by peaks of intensive care unit (ICU) admission rates. During these periods, progressive knowledge of the disease led to the development of specific therapeutic strategies. This retrospective study investigates whether this led to improvement in outcomes of COVID-19 patients admitted to ICU. Outcomes were evaluated in consecutive adult COVID-19 patients admitted to our ICU, divided into three waves based on the admission period: the first wave from February 25 Overall, 428 patients were included in the analysis: 102, 169, and 157 patients in the first, second, and third wave. The ICU and in-hospital crude mortalities were lower by 7% and 10% in the third wave compared to the other two waves (P>0.05). A higher number of ICU- and hospital-free days at day 90 was found in the third wave when compared to the other two waves (P=0.001). Overall, 62.6% underwent invasive ventilation, with decreasing requirement during the waves (P=0.002). The adjusted Cox model showed no difference in the hazard ratio (HR) for mortality among the waves. In the propensity-matched analysis the hospital mortality rate was reduced by 11% in the third wave (P=0.044). With application of best practice as known by the time of the first three waves of the pandemic, our study failed to identify a significant improvement in mortality rate when comparing the different waves of the COVID-19 pandemic, notwithstanding, the sub-analyses showed a trend in mortality reduction in the third wave. Rather, our study identified a possible positive effect of dexamethasone on mortality rate reduction and the increased risk of death related to bacterial infections in the three waves.

Sections du résumé

Background UNASSIGNED
The time-course of the coronavirus disease 2019 (COVID-19) pandemic was characterized by subsequent waves identified by peaks of intensive care unit (ICU) admission rates. During these periods, progressive knowledge of the disease led to the development of specific therapeutic strategies. This retrospective study investigates whether this led to improvement in outcomes of COVID-19 patients admitted to ICU.
Methods UNASSIGNED
Outcomes were evaluated in consecutive adult COVID-19 patients admitted to our ICU, divided into three waves based on the admission period: the first wave from February 25
Results UNASSIGNED
Overall, 428 patients were included in the analysis: 102, 169, and 157 patients in the first, second, and third wave. The ICU and in-hospital crude mortalities were lower by 7% and 10% in the third wave compared to the other two waves (P>0.05). A higher number of ICU- and hospital-free days at day 90 was found in the third wave when compared to the other two waves (P=0.001). Overall, 62.6% underwent invasive ventilation, with decreasing requirement during the waves (P=0.002). The adjusted Cox model showed no difference in the hazard ratio (HR) for mortality among the waves. In the propensity-matched analysis the hospital mortality rate was reduced by 11% in the third wave (P=0.044).
Conclusions UNASSIGNED
With application of best practice as known by the time of the first three waves of the pandemic, our study failed to identify a significant improvement in mortality rate when comparing the different waves of the COVID-19 pandemic, notwithstanding, the sub-analyses showed a trend in mortality reduction in the third wave. Rather, our study identified a possible positive effect of dexamethasone on mortality rate reduction and the increased risk of death related to bacterial infections in the three waves.

Identifiants

pubmed: 37426115
doi: 10.21037/jtd-22-764
pii: jtd-15-06-3218
pmc: PMC10323587
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3218-3227

Informations de copyright

2023 Journal of Thoracic Disease. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-764/coif). The authors have no conflicts of interest to declare.

Références

Am J Respir Crit Care Med. 2021 Mar 1;203(5):565-574
pubmed: 33306946
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Drug Dev Res. 2021 Jun;82(4):474-493
pubmed: 33251593
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Clin Microbiol Infect. 2021 Mar;27(3):389-395
pubmed: 33359375
Recenti Prog Med. 2014 Jan;105(1):9-24
pubmed: 24553592
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Anaesthesia. 2020 Oct;75(10):1340-1349
pubmed: 32602561
Rev Esp Quimioter. 2021 Sep;34 Suppl 1:57-59
pubmed: 34598429
Intensive Care Med. 2021 May;47(5):538-548
pubmed: 33852032
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Crit Care Explor. 2021 May 19;3(5):e0438
pubmed: 34079951
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Biomed Pharmacother. 2021 Jun;138:111518
pubmed: 33774315
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Lancet Reg Health Eur. 2021 Apr;3:100041
pubmed: 33870249
Anaesthesia. 2021 Mar;76 Suppl 3:10
pubmed: 32776536
Clin Infect Dis. 2009 Dec 1;49(11):1770-1; author reply 1771-2
pubmed: 19891568
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
Lancet Respir Med. 2021 Jul;9(7):773-785
pubmed: 34000238
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
Pathog Glob Health. 2020 Sep;114(6):281-282
pubmed: 32584660
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
PLoS One. 2021 May 6;16(5):e0251170
pubmed: 33956882
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434

Auteurs

Irene Coloretti (I)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Carlotta Farinelli (C)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Emanuela Biagioni (E)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Ilenia Gatto (I)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Elena Munari (E)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Lorenzo Dall'Ara (L)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Stefano Busani (S)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Marianna Meschiari (M)

Infectious Disease Unit, University Hospital of Modena, Modena, Italy.

Roberto Tonelli (R)

Respiratory Disease Unit, University Hospital of Modena, Modena, Italy.

Cristina Mussini (C)

Infectious Disease Unit, University Hospital of Modena, Modena, Italy.

Giovanni Guaraldi (G)

Infectious Disease Unit, University Hospital of Modena, Modena, Italy.

Andrea Cossarizza (A)

Immunology Laboratory, University of Modena and Reggio Emilia, Modena, Italy.

Enrico Clini (E)

Respiratory Disease Unit, University Hospital of Modena, Modena, Italy.

Massimo Girardis (M)

Intensive Care Unit, University Hospital of Modena, Modena, Italy.

Classifications MeSH